ReviewFrontiers in aging neuroscience2023
Subjective cognitive decline in patients with Parkinson's disease: an updated review.
Review in Frontiers in aging neuroscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 17 citations in OpenAlex.
- Gait Analysis for Identifying Normal Cognition, Subjective Cognitive Decline, and Mild Cognitive Impairment in Parkinson Disease: Diagnostic Study.JMIR mHealth and uHealth · 2026Article
- Parkinson's disease-subjective cognitive decline and health-related quality of life.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- The central cholinergic system as a therapeutic target in Parkinson's disease.Journal of Parkinson's disease · 2026Review
- Recommendations to Improve Healthcare Service Provision for Cognitive Impairment in People With Parkinson's Disease: A Mixed Methods Study of the Lived Experience Expert Perspective.Health expectations : an international journal of public participation in health care and health policy · 2026Article
- Data-driven clinical decision support tool for diagnosing mild cognitive impairment in Parkinson's disease.NPJ Parkinson's disease · 2026Article
- Diffusion tensor image analysis along the perivascular space (DTI-ALPS) in Parkinson's disease patients with subjective cognitive decline.Frontiers in aging neuroscience · 2026Article
- Multi-cohort machine learning identifies predictors of cognitive impairment in Parkinson's disease.NPJ digital medicine · 2025Article
- Associations between reversible and potentially reversible cognitive frailty and falls in community-dwelling older adults in China: a longitudinal study.BMC geriatrics · 2025Article
- Heterogeneity of cognitive progression and clinical predictors in Parkinson's disease-subjective cognitive decline.Journal of neurology · 2025Article
- Mitochondrial Dysfunction in Parkinson's Disease: A Contribution to Cognitive Impairment?International journal of molecular sciences · 2024Review
- Mild cognitive impairment in Parkinson's disease: current view.Frontiers in cognition · 2024Review
- Aging, not Parkinson's disease, decreases a recalibration of body ownership caused by vision-respiratory interaction.Frontiers in physiology · 2024Article
- Total burden of cerebral small vessel disease predict subjective cognitive decline in patients with Parkinson's disease.Frontiers in aging neuroscience · 2024Article
- Pathobiology of Cognitive Impairment in Parkinson Disease: Challenges and Outlooks.International journal of molecular sciences · 2023Review
- Subjective cognitive complaints in patients with progressive supranuclear palsy.Frontiers in neurology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cognitive impairment in patients with Parkinson's disease (PD) worsens the prognosis of PD and increases caregivers' burden and economic consequences. Recently, subjective cognitive decline (SCD), which refers to self-reported cognitive decline without detectable objective cognitive dysfunction, has been regarded as an at-risk state of mild cognitive impairment (MCI) and a prodromal stage for dementia in Alzheimer's disease (AD). However, studies on PD-SCD have thus far been scarce, and at present there is no consensus regarding the definition of SCD nor a gold standard as an evaluation tool. The present review aimed to look for an association between PD-SCD and objective cognitive function and found that PD with SCD occurred with brain metabolic changes, which were consistent with early aberrant pathological changes in PD. Moreover, PD patients with SCD were likely to progress to future cognitive impairment. It is necessary to establish a guideline for the definition and evaluation of SCD in PD. A larger sample size and more longitudinal investigations are needed to verify the predictive effectiveness of PD-SCD and to detect earlier subtle cognitive decline before MCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.